Clinical Trial Update: Activity of AVE1625 in Mild to Moderate Alzheimer's Patients. [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating AVE1625 in patients with mild-to-moderate Alzheimer's disease is summarized in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AVE1625

Snippet

Sponsor: Sanofi | Conditions: Alzheimer Disease | Phase 1, Phase 2 | Status: COMPLETED